Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 1, 2021Clinical TransplantationOpen Access

Bioavailability of once‐daily tacrolimus formulations used in clinical practice in the management of De Novo kidney transplant recipients: the better study

View Full Paper
Ask AI
Bookmark
Share

Authors

CRConstantino Fernández RiveraMRMaría Calvo RodríguezJPJosé Luís Poveda

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Rivera et al. (2021) studied this question.

synapsesocial.com/papers/6aa9211ae4c74ea01887827bhttps://doi.org/10.1111/ctr.14550
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Effectiveness and safety of the conversion to MeltDose® extended‐release tacrolimus from other formulations of tacrolimus in stable kidney transplant patients: A retrospective study2019 · 23 citations
  2. 2Conversion From Twice-Daily Tacrolimus Capsules to Once-Daily Extended-Release Tacrolimus (LCPT)2013 · 101 citations
  3. 3Comparison of the long-term outcomes of kidney transplantation: USA versus Spain2012 · 89 citations
  4. 4Novel Once-Daily Extended-Release Tacrolimus (LCPT) Versus Twice-Daily Tacrolimus in De Novo Kidney Transplants: One-Year Results of Phase III, Double-Blind, Randomized Trial2014 · 129 citations
  5. 5Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial2015 · 98 citations